Targetting of desmoglein 1 in inherited and acquired skin diseases

Clinical and Experimental Dermatology

Volumn 28, Issue 4, 2003, Pages 410-415

  Whittock, N Vincent ^a,b   Bower, C ^b  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CADHERIN; DESMOCOLLIN; DESMOGLEIN 1; PLAKOGLOBIN; PROTEIN PRECURSOR;

AUTOIMMUNE DISEASE; BULLOUS SKIN DISEASE; CALCIUM BINDING; DESMOSOME; DSG1 GENE; EPIDERMIS; EPITHELIUM; EXON; GENE; GENE CLUSTER; GENE MUTATION; GENE STRUCTURE; GENETICS; GENODERMATOSIS; HUMAN; KERATOSIS PALMOPLANTARIS; PEMPHIGUS FOLIACEUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SKIN DISEASE; STAPHYLOCOCCUS AUREUS; TOXIC EPIDERMAL NECROLYSIS;

CYTOSKELETAL PROTEINS; DESMOCOLLINS; DESMOGLEIN 1; DESMOGLEINS; DESMOPLAKINS; DESMOSOMES; FEMALE; GAMMA CATENIN; HUMANS; MALE; MUTATION; PEMPHIGUS; SKIN DISEASES, GENETIC; STAPHYLOCOCCAL SCALDED SKIN SYNDROME;

EID: 0038045492     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2003.01311.x     Document Type: Review

References (30)

1. Schmidt A, Heid HW, Schafer S et al. Desmosomes and cytoskeletal architecture in epithelial differentiation: cell type-specific plaque components and intermediate filament anchorage. Eur J Cell Biol 1994; 65: 229-45.
2. 2+-dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell-cell adhesion. J Cell Biol 1997; 138: 193-201.
3. Troyanovsky SM, Eshkind LG, Troyanovsky RB et al. Contributions of cytoplasmic domains of desmosomal cadherins to desmosome assembly and intermediate filament anchorage. Cell 1993; 72: 561-74.
4. Kowalczyk AP, Borgwardt JE, Green KJ. Analysis of desmosomal cadherin-adhesive function and stoichiometry of desmosomal cadherin-plakoglobin complexes. J Invest Dermatol 1996; 107: 293-300.
5. Bannon LJ, Cabrera BL, Stack MS et al. Isoform-specific differences in the size of desmosomal cadherin/catenin complexes. J Invest Dermatol 2001; 117: 1302-6.
6. Hunt DM, Rickman L, Whittock NV et al. Spectrum of dominant mutations in the desmosomal cadherin desmoglein 1, causing the skin disease striate palmoplantar keratoderma. Eur J Hum Genet 2001; 9: 197-203.
7. Whittock NV, Bower C. Genetic evidence for a novel human desmosomal cadherin, desmoglein 4. J Invest Dermatol 2003; 120: 523-30.
8. Hennies HC, Kuster W, Mischke D et al. Localization of a locus for the striated form of palmoplantar keratoderma to chromosome 18q near the desmosomal cadherin gene cluster. Hum Mol Genet 1995; 4: 1015-20.
9. Rickman L, Simrak D, Stevens HP et al. N-terminal deletion in a desmosomal cadherin causes the autosomal dominant skin disease striate palmoplantar keratoderma. Hum Mol Genet 1999; 8: 971-6.
10. Kljuic A, Gilead L, Martinez-Mir A et al. A nonsense mutation in the desmoglein 1 gene underlies striate keratoderma. Exp Dermatol 2003, in press.
11. Armstrong DK, McKenna KE, Purkis PE et al. Haploinsufficiency of desmoplakin causes a striate subtype of palmoplantar keratoderma. Hum Mol Genet 1999; 8: 143-8.
12. Whittock NV, Ashton GH, Dopping-Hepenstal PJ et al. Striate palmoplantar keratoderma resulting from desmoplakin haploinsufficiency. J Invest Dermatol 1999; 113: 940-6.
13. Whittock NV, Smith FJ, Wan H et al. Frameshift mutation in the V2 domain of human keratin 1 results in striate palmoplantar keratoderma. J Invest Dermatol 2002; 118: 838-44.
14. Lever WF. Pemphigus vulgaris. In: Lever, WF, ed. Pemphigus and Pemphigoid, 1st edn. Springfield, IL: Charles C. Thomas: 1965.
15. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869-77.
16. Stanley JR, Koulu L, Thivolet C. Distinction between epidermal antigens binding pemphigus vulgaris and pemphigus foliaceus autoantibodies. J Clin Invest 1984; 74: 313-20.
17. Labib RS, Rock B, Martins CR et al. Pemphigus foliaceus antigen: characterization of an immunoreactive tryptic fragment from BALB/c mouse epidermis recognized by all patients' sera and major autoantibody subclasses. Clin Immunol Immunopathol 1990; 57: 317-29.
18. Lin MS, Swartz SJ, Lopez A et al. T lymphocytes from a subset of patients with pemphigus vulgaris respond to both desmoglein-3 and desmoglein-1. J Invest Dermatol 1997; 109: 734-7.
19. Arteaga LA, Prisayanh PS, Warren SJ et al. A subset of pemphigus foliaceus patients exhibits pathogenic autoantibodies against both desmoglein-1 and desmoglein-3. J Invest Dermatol 2002; 118: 806-11.
20. Iwatsuki K, Takigawa M, Hashimoto T et al. Can pemphigus vulgaris become pemphigus foliaceus? J Am Acad Dermatol 1991; 25: 797-800.
21. Ishii K, Amagai M, Ohata Y et al. Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay. J Am Acad Dermatol 2000; 42: 859-61.
22. Cerna M, Fernandez-Vina M, Friedman H et al. Genetic markers for susceptibility to endemic Brazilian pemphigus foliaceus (fogo selvagem) in Xavante indians. Tissue Antigens 1993; 42: 138-40.
23. Moraes ME, Fernandez-Vina M, Lazaro A et al. An epitope in the third hypervariable region of the DRB1 gene is involved in the susceptibility to endemic pemphigus foliaceus (fogo selvagem) in three different Brazilian populations. Tissue Antigens 1997; 49: 35-40.
24. Scharf SJ, Friedmann A, Brautbar C et al. HLA class II allelic variation and susceptibility to pemphigus vulgaris. Proc Natl Acad Sci USA 1988; 85: 3504-8.
25. Sinha AA, Brautbar C, Szafer F et al. A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science 1988; 239: 1026-9.
26. Ladhani S, Joannou CL, Lochrie DP et al. Clinical, microbial, and biochemical aspects of the exfoliative toxins causing staphylococcal scalded-skin syndrome. Clin Microbiol Rev 1999; 12: 224-42.
27. Melish ME, Glasgow LA. The staphylococcal scalded-skin syndrome. N Engl J Med 1970; 282: 1114-9.
28. Hanakawa Y, Schechter NM, Lin C et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest 2002; 110: 53-60.
29. Amagai M, Matsuyoshi N, Wang ZH et al. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nature Med 2000; 6: 1275-7.
30. Amagai M, Yamaguchi T, Hanakawa Y et al. Staphylococcal exfoliative toxin B specifically cleaves desmoglein 1. J Invest Dermatol 2002; 118: 845-50.